1. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations
- Author
-
Hajime Kamiya, Mehmet Ceyhan, Konstantin Mironov, Gabriela Echániz-Aviles, Jay Lucidarme, Susan Meiring, Yanet Climent, Muhamed-Kheir Taha, Philippe De Wals, Bianca Stenmark, Dominique A. Caugant, Xilian Bai, Marco Aurélio Palazzi Sáfadi, Josefina Carlos, Caroline Trotter, Ener Cagri Dinleyici, Vinny Smith, Reinaldo Acevedo, Bingqing Zhu, Hannah Christensen, Zhujun Shao, Ray Borrow, Andromachi Karachaliou, Julio A. Vázquez, Ahmed Hakawi, Robert Steffen, Finlay Institute of Vaccines, Public Health England [London], Norwegian Institute of Public Health [Oslo] (NIPH), University of the East – Ramon Magsaysay Memorial Medical Center [Philippines], Faculty of Medicine [Hacettepe University], Hacettepe University = Hacettepe Üniversitesi, University of Bristol [Bristol], Université Laval [Québec] (ULaval), Eskisehir Osmangazi University, National Institute of Public Health = Instituto Nacional de Salud Pública [Cuernavaca, Mexique] (INSP), Ministry of Health [Riyadh], National Institute of Infectious Diseases [Tokyo], University of Cambridge [UK] (CAM), National Institute for Communicable Diseases [Johannesburg] (NICD), Central Research Institute of Epidemiology [Moscow], FCM Santa Casa de São Paulo School of Medical Sciences [São Paulo], Chinese Centre for Disease Control and Prevention, Meningitis Research Foundation [Bristol], Universität Zürich [Zürich] = University of Zurich (UZH), Örebro University Hospital [Örebro, Sweden], Centre National de Référence des Méningocoques et Haemophilus influenzae - National Reference Center Meningococci and Haemophilus influenzae (CNR), Institut Pasteur [Paris], Institute of Health Carlos III, R. Borrow, J. Lucidarme and X. Bai perform contract work for Public Health England on behalf of GSK, PATH, Sanofi Pasteur and Pfizer. M.K. Taha performs contract work for the Institut Pasteur funded by GSK, Pfizer and Sanofi Pasteur. S. Meiring has received grant funding for a meningococcal carriage study by Sanofi Pasteur. G. Enchaniz-Aviles has received support for research projects from GSK and Pfizer. J.A. Vázquez performs contract work for the Institute of Health Carlos III funded by GSK and Pfizer. P. De Wals has received research grants, and reimbursements of travel expenses from vaccine manufacturers including GSK, Novartis, Sanofi Pasteur, and Pfizer, as well as from governmental agencies including the Quebec Ministry of Health and Social Services, Health Canada, and the Public Health Agency of Canada. M.A.P. Sáfadi has received grants to support research projects and consultancy fees from GSK, Pfizer and Sanofi Pasteur. C. Trotter has received consulting fees from GSK and an honorarium from Sanofi-Pasteur for developing and delivering a modeling workshop at a previous GMI meeting. H. Christensen has received reimbursements of travel expenses and, for previous GMI meetings, honoraria, from Sanofi-Pasteur, consultancy fees from IMS Health and AstraZeneca all paid to her employer. She is supported by the NIHR Health Protection Research Unit in Evaluation of Interventions at the University of Bristol. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care., Institut Pasteur [Paris] (IP), and Sanofi Pasteur
- Subjects
0301 basic medicine ,Antibiotic resistance ,MESH: Anti-Bacterial Agents/administration & dosage ,MESH: Anti-Bacterial Agents/pharmacology ,MESH: Global Health ,Neisseria meningitidis ,medicine.disease_cause ,Global Health ,Disease Outbreaks ,MESH: Meningococcal Infections/epidemiology ,0302 clinical medicine ,Risk Factors ,MESH: Risk Factors ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,vaccine ,Drug Discovery ,Epidemiology ,030212 general & internal medicine ,MESH: Disease Outbreaks ,immunization program ,Vaccination ,3. Good health ,Anti-Bacterial Agents ,conjugate vaccine ,surveillance ,Molecular Medicine ,Epidemiology / Surveillance ,epidemiology ,bacterial meningitis ,serogroup ,medicine.medical_specialty ,Immunology ,MESH: Meningococcal Infections/microbiology ,Meningococcal Vaccines ,Polysaccharide Vaccine ,Meningococcal disease ,03 medical and health sciences ,Conjugate vaccine ,Drug Resistance, Bacterial ,MESH: Drug Resistance, Bacterial ,medicine ,Humans ,MESH: Meningococcal Vaccines/administration & dosage ,Pharmacology ,meningococcal disease ,High risk populations ,MESH: Humans ,business.industry ,MESH: Vaccination ,medicine.disease ,Virology ,polysaccharide vaccine ,Meningococcal Infections ,030104 developmental biology ,MESH: Meningococcal Infections/prevention & control ,business - Abstract
Introduction: The 2018 Global Meningococcal Initiative (GMI) meeting focused on evolving invasive meningococcal disease (IMD) epidemiology, surveillance, and protection strategies worldwide, with emphasis on emerging antibiotic resistance and protection of high-risk populations. The GMI is comprised of a multidisciplinary group of scientists and clinicians representing institutions from several continents. Areas covered: that the incidence and prevalence of IMD continually varies both geographically and temporally, and surveillance systems differ worldwide, the true burden of IMD remains unknown. Genomic alterations may increase the epidemic potential of meningococcal strains. Vaccination and (to a lesser extent) antimicrobial prophylaxis are the mainstays of IMD prevention. Experiences from across the globe advocate the use of conjugate vaccines, with promising evidence growing for protein vaccines. Multivalent vaccines can broaden protection against IMD. Application of protection strategies to high-risk groups, including individuals with asplenia, complement deficiencies and human immunodeficiency virus, laboratory workers, persons receiving eculizumab, and men who have sex with men, as well as attendees at mass gatherings, may prevent outbreaks. There was, however, evidence that reduced susceptibility to antibiotics was increasing worldwide. Expert commentary: The current GMI global recommendations were reinforced, with several other global initiatives underway to support IMD protection and prevention. This paper was in part supported by Sanofi Pasteur. Sí
- Published
- 2018
- Full Text
- View/download PDF